BridgeBio Pharma (BBIO) shares were falling past 5% in recent Thursday trading after KKR Genetic Disorder disclosed the sale of 6 million BridgeBio shares in a regulatory filing.
KKR Genetic Disorder said in the filing that before BridgeBio's initial public offering, it bought about 167.7 million preferred units of BridgeBio for roughly $170.6 million in a series of financing deals.
The preferred units held by KKR Genetic Disorder were converted into about 34.3 million shares of BridgeBio, KKR Genetic Disorder said.
Price: 33.12, Change: -1.86, Percent Change: -5.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.